National Patient Advocate Foundation actively supports regulatory proposals that improve access to healthcare. As part of its Federal Government Affairs Program, NPAF submits comments to Regulatory Agencies, including the Food and Drug Administration (FDA) and the Department of Health and Human Services (DHHS), in an effort to incorporate the patient voice in regulatory decisions.

NPAF Comments on Revisions to Payment Policies Under the Physician Fee Schedule - August 2010

NPAF Comments on Hospital Outpatient Prospective Patient System - August 2010

NPAF Comments on Grandfathered Health Plans - August 2010

NPAF Comments on Disclosure Policies of the U.S. Food and Drug Administration - July 2010

NPAF Comments on the use of Erythropoietin Stimulating Agents (ESAs) for the Treatment of Chronic Kidney Disease (CKD) and Dialysis-related Anemia - July 2010

NPAF Comments on Medical Loss Ratios - May 2010

NPAF Comments on Prescription Drug User Fee Act Reauthorization - May 2010

NPAF Comments to MEDPAC - April 2010

NPAF Comments to Electronic Health Record Incentive Program - March 2010

NPAF Comments to MEDCAC regarding Erythropoiesis-Stimulating Agents (ESAs) in Anemia Related to Kidney Disease - February 2010

NPAF Comments on the Policy and Technical Changes to the Medicare Advantage and the Medicare Prescription Drug Benefit Program - December 2009

NPAF Comments on 2010 Hospital Outpatient Prospective Payment Systems - August 2009

NPAF Comments on Physician Fee Schedule & Exhibit 1 - August 2009    

NPAF Comments on Advisory Committee for Reproductive Health Drugs Review of denosumab - July 2009

NPAF Comments on 2010 Hospital Inpatient Prospective Payment Systems

View Archived Comments